Citigroup’s Rosetta Genomics Ltd. ROSG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-84
| Closed | – | – | 7918 |
|
|
2018
Q1 | $0 | Hold |
84
| – | – | ﹤0.01% | 7859 |
|
|
2017
Q4 | $0 | Hold |
84
| – | – | ﹤0.01% | 7813 |
|
|
2017
Q3 | $0 | Hold |
84
| – | – | ﹤0.01% | 7692 |
|
|
2017
Q2 | $0 | Hold |
84
| – | – | ﹤0.01% | 7712 |
|
|
2017
Q1 | $0 | Buy |
84
+1
| +1% | +$5 | ﹤0.01% | 7480 |
|
|
2016
Q4 | $0 | Hold |
83
| – | – | ﹤0.01% | 7451 |
|
|
2016
Q3 | $1K | Hold |
83
| – | – | ﹤0.01% | 7021 |
|
|
2016
Q2 | $1K | Sell |
83
-21
| -20% | -$299 | ﹤0.01% | 7023 |
|
|
2016
Q1 | $1K | Buy |
104
+19
| +22% | +$242 | ﹤0.01% | 7388 |
|
|
2015
Q4 | $1K | Sell |
85
-30
| -26% | -$647 | ﹤0.01% | 7477 |
|
|
2015
Q3 | $3K | Buy |
115
+32
| +39% | +$1.09K | ﹤0.01% | 6970 |
|
|
2015
Q2 | $3K | Sell |
83
-15
| -15% | -$642 | ﹤0.01% | 7065 |
|
|
2015
Q1 | $4K | Buy |
98
+15
| +18% | +$568 | ﹤0.01% | 6826 |
|
|
2014
Q4 | $2K | Sell |
83
-7
| -8% | -$227 | ﹤0.01% | 6906 |
|
|
2014
Q3 | $4K | Sell |
90
-587
| -87% | -$26.7K | ﹤0.01% | 6688 |
|
|
2014
Q2 | $36K | Buy |
677
+260
| +62% | +$12.9K | ﹤0.01% | 5402 |
|
|
2014
Q1 | $25K | Sell |
417
-31
| -7% | -$1.6K | ﹤0.01% | 5916 |
|
|
2013
Q4 | $16K | Sell |
448
-92
| -17% | -$3.19K | ﹤0.01% | 6251 |
|
|
2013
Q3 | $21K | Buy |
540
+358
| +197% | +$14.5K | ﹤0.01% | 5894 |
|
|
2013
Q2 | $7K | Buy |
+182
| New | +$8.09K | ﹤0.01% | 6239 |
|
Other funds holding ROSG
Citigroup's ROSG Position: Q2 2018 in Review
Citigroup sold out of Rosetta Genomics Ltd. (ROSG) in Q2 2018, closing a stake of 84 shares.
Citigroup first reported a position in ROSG in Q2 2013 and held it in 20 quarters. The position peaked at $36K in Q2 2014. 2 funds tracked by Wall St. Rank hold ROSG as of Q2 2018.
- Citigroup reported no remaining Rosetta Genomics Ltd. position as of Q2 2018 after selling out during the quarter.
- Citigroup sold 84 Rosetta Genomics Ltd. shares in Q2 2018.
- Citigroup first reported a position in Rosetta Genomics Ltd. in Q2 2013 and held it in 20 quarters.
- Citigroup's Rosetta Genomics Ltd. position peaked at $36K in Q2 2014.
- 2 funds tracked by Wall St. Rank held Rosetta Genomics Ltd. as of Q2 2018.
Based on Citigroup's 13F filing for Q2 2018, filed 10 Aug 2018.